Autobio Diagnostics (603658) investor relations material

Executive summary

• Revenue for Q3 2025 was RMB 1.07 billion, down 9.04% year-over-year; year-to-date revenue was RMB 3.13 billion, down 7.48% year-over-year.

• Net profit attributable to shareholders for Q3 was RMB 288.5 million, down 14.3% year-over-year; year-to-date net profit was RMB 859.5 million, down 10.11% year-over-year.

• Basic and diluted EPS for Q3 was RMB 0.50, down 15.25% year-over-year; year-to-date EPS was RMB 1.50, down 9.09% year-over-year.

Financial highlights

• Gross margin improved as cost of sales decreased to RMB 1.10 billion from RMB 1.16 billion year-over-year.

• Operating profit for the first nine months was RMB 952.2 million, compared to RMB 1.06 billion in the prior year period.

• Net cash flow from operating activities for the first nine months was RMB 845.4 million, down 10.91% year-over-year.

• Total assets at Q3-end were RMB 11.73 billion, down 1.25% from year-end 2024.

• Shareholders’ equity increased 1.51% to RMB 8.75 billion compared to year-end 2024.

Outlook and guidance

• No explicit forward-looking guidance provided, but the report notes continued focus on core business and operational efficiency.